Sangamo Therapeutics (NASDAQ:SGMO) Posts Earnings Results, Misses Expectations By $0.02 EPS

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02), Zacks reports. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.70 million.

Sangamo Therapeutics Stock Up 2.3 %

Shares of SGMO traded up $0.02 during mid-day trading on Friday, reaching $0.86. 1,909,052 shares of the stock traded hands, compared to its average volume of 7,675,412. The firm has a market cap of $179.02 million, a price-to-earnings ratio of -1.14 and a beta of 1.49. The stock has a fifty day simple moving average of $1.07 and a 200 day simple moving average of $1.40. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18.

Analyst Upgrades and Downgrades

SGMO has been the topic of several analyst reports. Truist Financial decreased their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Jefferies Financial Group decreased their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating on the stock in a research report on Tuesday, December 31st. Wells Fargo & Company decreased their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research report on Tuesday, December 31st. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.17.

Remove Ads

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.